Premium
Cross‐reactivity of cell‐selective CRRETAWAC peptide with human and porcine endothelial cells
Author(s) -
Dudash Lynn A.,
Kligman Faina L.,
Bastijanic Jennifer M.,
KottkeMarchant Kandice,
Marchant Roger E.
Publication year - 2014
Publication title -
journal of biomedical materials research part a
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.849
H-Index - 150
eISSN - 1552-4965
pISSN - 1549-3296
DOI - 10.1002/jbm.a.34960
Subject(s) - peptide , fibronectin , adhesion , materials science , cell adhesion , in vitro , biophysics , in vivo , platelet , biomedical engineering , cell , microbiology and biotechnology , biochemistry , chemistry , biology , medicine , immunology , composite material
We report on the cross‐reactivity of the cell adhesive peptide CRRETAWAC between human and porcine endothelial cells (ECs). CRRETAWAC is a phage display derived peptide which has been shown to bind the α 5 β 1 receptor on human ECs, but does not bind platelets and thus could be incorporated into a coating for cardiovascular biomaterials that resists platelet adhesion and thrombosis, while allowing for endothelialization. To determine the cross‐reactivity of the peptide, attachment and growth of human and porcine ECs on CRRETAWAC fluorosurfactant polymer (FSP) coated surfaces was explored. CRRETAWAC FSP was synthesized and characterized by mass spectrometry, NMR, and IR spectroscopy. pEC attachment and growth on CRRETAWAC FSP was similar to the positive controls, human fibronectin and RGD FSP, achieving confluence in 72 h. Initial adhesion on CRRETAWAC FSP was also similar for porcine and human ECs. Blocking with soluble CRRETAWAC peptide reduced adhesion to CRRETAWAC coated surfaces by over 50%, indicating that the pECs specifically bind CRRETAWAC peptide. With this study, we have demonstrated that CRRETAWAC peptide coated surfaces are capable of binding porcine ECs in a specific manner and supporting a confluent layer of pECs. In vitro validation of the porcine model was critical for ensuring the best chance of success for the in vivo testing of CRRETAWAC coated ePTFE vascular grafts. © 2013 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 102A: 2857–2863, 2014.